Antibiotic
(Redirected from History of antibiotics)
Antimicrobial Agents
Antimicrobial agents are substances produced by microorganisms that selectively suppress the growth of or kill other microorganisms at very low concentrations. This definition excludes natural substances that also inhibit microorganisms but are produced by higher forms (e.g., antibodies) or those produced by microbes but are needed in high concentrations (such as ethanol, lactic acid, and H2O2).
Initially, the term "chemotherapeutic agent" was restricted to synthetic compounds. However, since many antibiotics and their analogues have been synthesized, this criterion has become irrelevant. Both synthetic and microbiologically produced drugs need to be included together. The term Antimicrobial agent (AMA) is used to designate synthetic as well as naturally obtained drugs that attenuate microorganisms.
History
The history of chemotherapy may be divided into three phases:
Phase 1: The Period of Empirical Use
This phase includes the use of:
- "Mouldy curd" by the Chinese on boils
- Chaulmoogra oil by the Hindus in leprosy
- Chenopodium by the Aztecs for intestinal worms
- Mercury by Paracelsus (16th century) for syphilis
- Cinchona bark (17th century) for fevers
Phase 2: Ehrlich's Phase of Dyes and Organometallic Compounds (1890–1935)
With the discovery of microbes in the latter half of the 19th century and their role in causing many diseases, Paul Ehrlich proposed that if certain dyes could selectively stain microbes, they could also be selectively toxic to these organisms. He experimented with methylene blue, trypan red, and others. Ehrlich developed the arsenicals—atoxyl for sleeping sickness, arsphenamine in 1906, and neoarsphenamine in 1909 for syphilis. He coined the term "chemotherapy" because he used drugs of known chemical structure (unlike most other drugs in use at that time) and demonstrated that selective attenuation of infecting parasites was possible.
Phase 3: The Modern Era of Chemotherapy
This phase began in 1935 when Gerhard Domagk demonstrated the therapeutic effect of Prontosil, a sulfonamide dye, in pyogenic infection. It was soon realized that the active moiety was paraamino benzene sulfonamide, and the dye part was not essential. Sulfapyridine (M & B 693) was the first sulfonamide to be marketed in 1938.
Louis Pasteur demonstrated the phenomenon of antibiosis in 1877: growth of anthrax bacilli in urine was inhibited by air-borne bacteria. In 1929, Alexander Fleming discovered that a diffusible substance was elaborated by Penicillium mould, which could destroy Staphylococcus on the culture plate. He named this substance penicillin but could not purify it. Howard Florey and Ernst Chain followed up this observation in 1939, culminating in the clinical use of penicillin in 1941. Due to its great potential for treating war wounds, commercial manufacture of penicillin soon began.
In the 1940s, Selman Waksman and his colleagues undertook a systematic search for Actinomycetes as a source of antibiotics and discovered streptomycin in 1944. This group of soil microbes proved to be a treasure trove of antibiotics, and soon tetracyclines, chloramphenicol, erythromycin, and many others followed. All three groups of scientists—Domagk, Fleming-Chain-Florey, and Waksman—received the Nobel Prize for their discoveries.
Semisynthetic Antibiotics
In the past 40 years, the emphasis has shifted from searching for new antibiotic-producing organisms to developing semisynthetic derivatives of older antibiotics with more desirable properties or differing spectrum of activity. A few novel synthetic AMAs, such as fluoroquinolones and oxazolidinones, have also been produced.
Staphylococcus Aureus Susceptibility
Staphylococcus aureus susceptibility refers to the ability of this bacterium to be affected by certain antimicrobial agents. The susceptibility of a particular strain of Staphylococcus aureus to different antibiotics can vary, making it essential to choose the appropriate antimicrobial agent for treatment.
(c) The modern era of chemotherapy was ushered by Domagk in 1935 by demonstrating the therapeutic effect of Prontosil, a sulfonamide dye, in pyogenic infection. It was soon realized that the active moiety was paraamino benzene sulfonamide, and the dye part was not essential. Sulfapyridine (M & B 693) was the first sulfonamide to be marketed in 1938.
Pasteur
The phenomenon of antibiosis was demonstrated by Pasteur in 1877: growth of anthrax bacilli in urine was inhibited by air-borne bacteria. Fleming (1929) found that a diffusible substance was elaborated by Penicillium mould which could destroy Staphylococcus on the culture plate. He named this substance penicillin but could not purify it. Chain and Florey followed up this observation in 1939 which culminated in the clinical use of penicillin in 1941. Because of the great potential of this discovery in treating war wounds, commercial manufacture of penicillin soon started.
Waksman
In the 1940s, Waksman and his colleagues undertook a systematic search of Actinomycetes as source of antibiotics and discovered streptomycin in 1944. This group of soil microbes proved to be a treasure-house of antibiotics and soon tetracyclines, chloramphenicol, erythromycin and many others followed. All three groups of scientists, Domagk, Fleming-Chain-Florey and Waksman received the Nobel Prize for their discoveries.
Semisynthetic antibiotics
In the past 40 years emphasis has shifted from searching new antibiotic producing organisms to developing semisynthetic derivatives of older antibiotics with more desirable properties or differing spectrum of activity. Few novel synthetic AMAs, e.g. fluoroquinolones, oxazolidinones have also been produced.
CLASSIFICATION
Antimicrobial drugs can be classified in many ways:
- Chemical structure
- Sulfonamides and related drugs: Sulfadiazine and others, Sulfones—Dapsone (DDS), Para aminosalicylic acid (PAS).
- Diaminopyrimidines: Trimethoprim, Pyrimethamine.
- Quinolones: Nalidixic acid, Norfloxacin, Ciprofloxacin, Gatifloxacin, etc.
- β-Lactam antibiotics: Penicillins, Cephalosporins, Monobactams, Carbapenems.
- Tetracyclines: Oxytetracycline, Doxycycline, etc.
- Nitrobenzene derivative: Chloramphenicol.
- Aminoglycosides: Streptomycin, Gentamicin, Amikacin, Neomycin, etc.
- Macrolide antibiotics: Erythromycin, Clarithromycin, Azithromycin, etc.
- Lincosamide antibiotics: Lincomycin, Clindamycin.
- Glycopeptide antibiotics: Vancomycin, Teicoplanin.
- Oxazolidinone: Linezolid.
- Polypeptide antibiotics: Polymyxin-B, Colistin, Bacitracin, Tyrothricin.
- Nitrofuran derivatives: Nitrofurantoin, Furazolidone.
- Nitroimidazoles: Metronidazole, Tinidazole, etc.
- Nicotinic acid derivatives: Isoniazid, Pyrazinamide, Ethionamide.
- Polyene antibiotics: Nystatin, Amphotericin-B, Hamycin.
- Azole derivatives: Miconazole, Clotrimazole, Ketoconazole, Fluconazole.
- Others: Rifampin, Spectinomycin, Sod. fusidate, Cycloserine, Viomycin, Ethambutol, Thiacetazone, Clofazimine, Griseofulvin.
- Inhibit cell wall synthesis: Penicillins, Cephalosporins, Cycloserine, Vancomycin, Bacitracin.
- Cause leakage from cell membranes: Polypeptides—Polymyxins, Colistin, Bacitracin. Polyenes—Amphotericin B]], Nystatin, Hamycin.
- Inhibit protein synthesis: Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, Linezolid.
- Cause misreading of m-RNA code and affect permeability: Aminoglycosides—Streptomycin, Gentamicin, etc.
- Inhibit DNA gyrase: Fluoroquinolones— Ciprofloxacin and others.
- Interfere with DNA function: Rifampin, Metronidazole.
- Interfere with DNA synthesis: Acyclovir, Zidovudine.
- Interfere with intermediary metabolism: Sulfonamides, Sulfones, PAS, Trimethoprim, Pyrimethamine, Ethambutol.
- Type of organisms against which primarily active
- Antibacterial: Penicillins, Aminoglycosides, Erythromycin, etc.
- Antifungal: Griseofulvin, Amphotericin B, Ketoconazole, etc.
- Antiviral: Acyclovir, Amantadine, Zidovudine, etc.
- Antiprotozoal: Chloroquine, Pyrimethamine, Metronidazole, Diloxanide, etc.
- Anthelmintic: Mebendazole, Pyrantel, Niclosamide, Diethyl carbamazine, etc.
- Spectrum of activity
- Narrow-spectrum: Penicillin G, Streptomycin, Erythromycin.
- Broad-spectrum: Tetracyclines, Chloramphenicol.
- Type of action
- Primarily bacteriostatic: Sulfonamides, Erythromycin, Tetracyclines, Ethambutol, Chloramphenicol, Clindamycin, Linezolid.
- Primarily bactericidal: Penicillins, Cephalosporins, Aminoglycosides, Vancomycin, Polypeptides, Nalidixic acid, Rifampin, Ciprofloxacin, Isoniazid, Metronidazole, Pyrazinamide, Cotrimoxazole.
- Antibiotics are obtained from
- Fungi: Penicillin, Griseofulvin, Cephalosporin.
- Bacteria: Polymyxin B, Tyrothricin, Colistin, Aztreonam, Bacitracin.
- Actinomycetes: Aminoglycosides, Macrolides, Tetracyclines, Polyenes, Chloramphenicol.
Overuse of antibiotics
Antibiotics save lives, but any time antibiotics are used, they can cause side effects and lead to antibiotic resistance. In U.S. doctors’ offices and emergency departments, at least 47 million antibiotic prescriptions each year are unnecessary, which makes improving antibiotic prescribing and use a national priority, according to the CDC.
Antibiotic resistance
Antibiotic resistance is one of the biggest public health challenges of our time. Each year in the U.S., at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die, according to the CDC.
History of antibiotic resistance
Penicillin, the first commercialized antibiotic, was discovered in 1928 by Alexander Fleming. Ever since, there has been discovery and acknowledgement of resistance alongside the discovery of new antibiotics. In fact, germs will always look for ways to survive and resist new drugs. More and more, germs are sharing their resistance with one another, making it harder for us to keep up.
Select Germs Showing Resistance Over Time
| Antibiotic Approved or Released | Year Released | Resistant Germ Identified | Year Identified |
|---|---|---|---|
| Penicillin | 1941 |
Penicillin-resistant Staphylococcus aureus Penicillin-resistant Streptococcus pneumoniae Penicillinase-producing Neisseria gonorrhoeae |
1942 1967 1976 |
| Vancomycin | 1958 |
Plasmid-mediated vancomycin-resistant Enterococcus faecium Vancomycin-resistant Staphylococcus aureus |
1988 2002 |
| Amphotericin B | 1959 | Amphotericin B-resistant Candida auris | 2016 |
| Methicillin | 1960 | Methicillin-resistant Staphylococcus aureus | 1960 |
| Extended-spectrum cephalosporins | 1980 (Cefotaxime) | Extended-spectrum beta-lactamase- producing Escherichia coli | 1983 |
| Azithromycin | 1980 | Azithromycin-resistant Neisseria gonorrhoeae | 2011 |
| Imipenem | 1985 | Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae | 1996 |
| Ciprofloxacin | 1987 | Ciprofloxacin-resistant Neisseria gonorrhoeae | 2007 |
| Fluconazole | 1990 (FDA approved) | Fluconazole-resistant Candida | 1988 |
| Caspofungin | 2001 | Caspofungin-resistant Candida | 2004 |
| Daptomycin | 2003 | Daptomycin-resistant methicillin-resistant Staphylococcus aureus | 2004 |
| Ceftazidime-avibactam | 2015 | Ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae | 2015 |
Antibiotic stewardship
Antibiotic stewardship is the effort to measure antibiotic prescribing; to improve antibiotic prescribing by clinicians and use by patients so that antibiotics are only prescribed and used when needed; to minimize misdiagnoses or delayed diagnoses leading to underuse of antibiotics; and to ensure that the right drug, dose, and duration are selected when an antibiotic is needed.
Benefits of antibiotic stewardship
Antibiotic stewardship can be used in all health care settings in which antibiotics are prescribed and remains a cornerstone of efforts aimed at improving antibiotic-related patient safety and slowing the spread of antibiotic resistance.
Goal of antibiotic stewardship
The goal of antibiotic stewardship is to maximize the benefit of antibiotic treatment while minimizing harm both to individual persons and to communities.
| This article is a medical stub. You can help WikiMD by expanding it! | |
|---|---|
| Use of antimicrobials | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Concepts in infectious disease (Outline) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD